GeoVax Labs’ (GOVX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report released on Thursday,Benzinga reports. D. Boral Capital currently has a $18.00 price target on the stock.

GeoVax Labs Stock Performance

GOVX stock opened at $1.02 on Thursday. The company has a market capitalization of $14.12 million, a PE ratio of -0.18 and a beta of 3.70. GeoVax Labs has a one year low of $0.88 and a one year high of $11.18. The company’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.99.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million. On average, research analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Trading of GeoVax Labs

A number of institutional investors have recently modified their holdings of the company. Northern Trust Corp purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $29,000. Geode Capital Management LLC increased its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the period. Virtu Financial LLC bought a new position in GeoVax Labs in the third quarter worth about $97,000. Finally, Citadel Advisors LLC purchased a new stake in GeoVax Labs in the fourth quarter worth about $104,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.